[Platelet inhibitors: old and new].
Platelet inhibiting drugs are mainly used to prevent arterial thrombosis complicating atherosclerosis. Numerous clinical trials have delineated their clinical indications and precise guidelines are internationally available. The mechanism of action of aspirin is well understood: inhibition of platelet synthesis of thromboxane, and there is a pretty good relationship between pharmacology at the molecular and cellular levels and clinical results. The recently available drugs are the following. Clopidogrel is a thienopyridine, which irreversibly inhibits platelet activation by ADP interacting with the recently cloned P2Y12 receptor. There are also inhibitors of the fibrinogen binding to its platelet receptor, the glycoprotein IIb/IIIa complex, which is the key mechanism of platelet aggregation. These new drugs are widely used in patients with active coronary artery disease, on top of aspirin.
Lecompte
Thomas
T
Université Henri Poincaré Nancy-1, EA 3452-CHU de Nancy, service d'hématologie biologique, France.
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000150:complications; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003327:Coronary Disease / Q000150:complications; D004176:Dipyridamole / Q000627:therapeutic use; D016903:Drug Monitoring; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008565:Membrane Proteins; D018579:Patient Selection; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D018048:Receptors, Purinergic P2 / Q000187:drug effects; D058925:Receptors, Purinergic P2Y12; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013931:Thromboxanes / Q000502:physiology; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D008565:Membrane Proteins; C548576:P2RY12 protein, human; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D018048:Receptors, Purinergic P2; D058925:Receptors, Purinergic P2Y12; D013931:Thromboxanes; D004176:Dipyridamole; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab
Inhibiteurs du fonctionnement plaquettaire: anciens et nouveaux.